CN108602858A - 嵌合rsv、免疫原性组合物以及使用方法 - Google Patents

嵌合rsv、免疫原性组合物以及使用方法 Download PDF

Info

Publication number
CN108602858A
CN108602858A CN201680072681.XA CN201680072681A CN108602858A CN 108602858 A CN108602858 A CN 108602858A CN 201680072681 A CN201680072681 A CN 201680072681A CN 108602858 A CN108602858 A CN 108602858A
Authority
CN
China
Prior art keywords
rsv
protein
gene
virus
immunogenic composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680072681.XA
Other languages
English (en)
Chinese (zh)
Inventor
马丁·L·摩尔
克里斯蒂娜·罗斯塔德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AMORY UNIV
Original Assignee
AMORY UNIV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AMORY UNIV filed Critical AMORY UNIV
Publication of CN108602858A publication Critical patent/CN108602858A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18521—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18561—Methods of inactivation or attenuation
    • C12N2760/18562—Methods of inactivation or attenuation by genetic engineering

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
CN201680072681.XA 2015-10-29 2016-10-27 嵌合rsv、免疫原性组合物以及使用方法 Pending CN108602858A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562247962P 2015-10-29 2015-10-29
US62/247,962 2015-10-29
US201662334547P 2016-05-11 2016-05-11
US62/334,547 2016-05-11
PCT/US2016/058976 WO2017075125A1 (en) 2015-10-29 2016-10-27 Chimeric RSV, Immunogenic Compositions, and Methods of Use

Publications (1)

Publication Number Publication Date
CN108602858A true CN108602858A (zh) 2018-09-28

Family

ID=58630734

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680072681.XA Pending CN108602858A (zh) 2015-10-29 2016-10-27 嵌合rsv、免疫原性组合物以及使用方法

Country Status (10)

Country Link
US (2) US11235050B2 (enExample)
EP (1) EP3368547A4 (enExample)
JP (2) JP7311872B2 (enExample)
KR (1) KR20180085730A (enExample)
CN (1) CN108602858A (enExample)
BR (1) BR112018008708A2 (enExample)
CA (1) CA3003726A1 (enExample)
MX (1) MX2018005462A (enExample)
SG (1) SG11201803581VA (enExample)
WO (1) WO2017075125A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2854673T3 (es) 2013-03-14 2021-09-22 Univ Emory VSR recombinante con mutaciones silenciosas, vacunas y métodos relacionados con ello
US9630994B2 (en) 2014-11-03 2017-04-25 University Of Washington Polypeptides for use in self-assembling protein nanostructures
EP3439672B1 (en) 2016-04-05 2020-11-25 Janssen Vaccines & Prevention B.V. Stabilized soluble pre-fusion rsv f protein for use in the prophylaxis of rsv infection
AU2018249533C1 (en) 2017-04-04 2023-10-12 Institute For Research In Biomedicine Self-assembling protein nanostructures displaying paramyxovirus and/or pneumovirus f proteins and their use
US11771755B2 (en) 2018-02-28 2023-10-03 University Of Washington Self-asssembling nanostructure vaccines
MX2021005607A (es) * 2018-11-13 2021-06-30 Janssen Vaccines & Prevention Bv Proteinas f de prefusion del vrs estabilizadas.
CA3211412A1 (en) * 2021-04-08 2022-10-13 Codagenix Inc. Method of eliciting an immune response against respiratory syncytial virus
US12304929B2 (en) * 2021-04-12 2025-05-20 Sk Bioscience Co., Ltd. Recombinant RSV live vaccine strain and the preparing method thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001089562A1 (en) * 2000-05-25 2001-11-29 Medimmune, Inc. F-protein epitope-based vaccine for respiratory syncytial virus infection
CN103842374A (zh) * 2011-05-13 2014-06-04 诺华股份有限公司 融合前的rsv f抗原
CA2905571A1 (en) * 2013-03-14 2014-09-18 Mucosis B.V. Heat-stable respiratory syncytial virus prefusion f protein oligomers and their use in immunological compositions
WO2014152534A1 (en) * 2013-03-14 2014-09-25 Emory University Recombinant rsv with silent mutations, vaccines, and methods related thereto

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5583024A (en) 1985-12-02 1996-12-10 The Regents Of The University Of California Recombinant expression of Coleoptera luciferase
IL105456A (en) 1992-04-21 1996-12-05 American Home Prod Vaccines of attenuated respiratory syncytial virus
AT401526B (de) 1993-02-10 1996-09-25 Scheirer Winfried Reagenzlösung zur stabilisierung der lumineszenz bei der luciferasemessung
PT702085E (pt) 1994-07-18 2004-04-30 Karl Klaus Conzelmann Virus de arn de cadeia negativa nao segmentada infeccioso recombinante
US7465574B2 (en) 1994-09-30 2008-12-16 Medimmune, Llc Recombinant RSV virus expression systems and vaccines
CA2230033C (en) 1995-09-27 2010-01-26 Peter L. Collins Production of infectious respiratory syncytial virus from cloned nucleotide sequences
US6689367B1 (en) 1995-09-27 2004-02-10 The United States Of America As Represented By The Department Of Health And Human Services Production of attenuated chimeric respiratory syncytial virus vaccines from cloned nucleotide sequences
US7485440B2 (en) 1995-09-27 2009-02-03 The United States Of America As Represented By The Department Of Health And Human Services Production of attenuated respiratory syncytial virus vaccines involving modification of M2 ORF2
US7846455B2 (en) 1996-07-15 2010-12-07 The United States Of America As Represented By The Department Of Health And Human Services Attenuated chimeric respiratory syncytial virus
US6713066B1 (en) 1996-07-15 2004-03-30 The United States Of America As Represented By The Department Of Health And Human Services Production of attenuated respiratory syncytial virus vaccines involving modification of M2 ORF2
US6923971B2 (en) 1995-09-27 2005-08-02 The United States Of America As Represented By The Department Of Health & Human Services Respiratory syncytial virus vaccines expressing protective antigens from promoter-proximal genes
US6214805B1 (en) 1996-02-15 2001-04-10 The United States Of America As Represented By The Department Of Health And Human Services RNase L activators and antisense oligonucleotides effective to treat RSV infections
BR9710363A (pt) 1996-07-15 2000-01-11 Us Gov Health & Human Serv "vìrus sincicial respirátorio recombinante infeccioso isolado, partìcula do mesmo, processos para estimular o sistema imunológico de um indivìduo para induzir proteção contra o vìrus sincicial respiratório e para produzir uma partìcula de vìrus sincicial respiratório recombinante, vacina para induzir proteção contra o vìrus sincicial respiratório recombinante composição e ceta de vìrus sincicial respiratório recombinante"
US6699476B1 (en) 1996-07-15 2004-03-02 Peter L. Collins Production of recombinant respiratory syncytial viruses expressing immune modulatory molecules
US5976796A (en) 1996-10-04 1999-11-02 Loma Linda University Construction and expression of renilla luciferase and green fluorescent protein fusion genes
US6074859A (en) 1997-07-08 2000-06-13 Kikkoman Corporation Mutant-type bioluminescent protein, and process for producing the mutant-type bioluminescent protein
US20040005542A1 (en) 2001-06-22 2004-01-08 Krempl Christine D Respiratory syncytial virus vaccines expressing protective antigens from promotor- proximal genes
AU2004226369A1 (en) 2003-03-28 2004-10-14 Medimmune, Llc Compositions and methods involving respiratory syncytial virus subgroup B strain 9320
EP1699919B1 (en) 2003-12-24 2017-01-11 De Staat der Nederlanden, Vertegenwoordigd Door de Minister Van Volksgezondheid, Welzijn en Sport A respiratory syncytial virus with a genomic deficiency complemented in trans
EP3312272B1 (en) 2004-10-08 2019-08-28 The Government of The United States of America as represented by The Secretary of The Department of Health and Human Services Modulation of replicative fitness by using less frequently used synonymous codons
US7951384B2 (en) 2005-08-05 2011-05-31 University Of Massachusetts Virus-like particles as vaccines for paramyxovirus
US8772256B2 (en) 2006-11-30 2014-07-08 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Codon modified immunogenic compositions and methods of use
MX2009010549A (es) 2007-03-30 2010-03-15 Univ New York State Res Found Virus atenuados utiles para vacunas.
US8580270B2 (en) 2008-09-30 2013-11-12 University Of Massachusetts Respiratory synctial virus (RSV) sequences for protein expression and vaccines
AU2009311287C1 (en) 2008-11-05 2015-02-19 Merck Sharp & Dohme Corp. Live, attentuated respiratory syncytial virus
HRP20160859T1 (hr) 2008-12-09 2016-09-23 Novavax, Inc. Modificirani proteini rsv f i postupci njihove upotrebe
EP4218799A1 (en) 2009-07-15 2023-08-02 GlaxoSmithKline Biologicals S.A. Rsv f protein compositions and methods for making same
US20110097358A1 (en) 2009-10-12 2011-04-28 Techno Vax, Inc. RESPIRATORY SYNCYTIAL VIRUS (RSV) VIRUS-LIKE PARTICLES (VLPs)
US10227569B2 (en) 2011-04-12 2019-03-12 Emory University Respiratory syncytial virus expression vectors
CA2840982C (en) 2011-07-06 2022-06-07 Vira BITKO Human respiratory syncytial virus vaccine
US8816081B2 (en) 2012-08-06 2014-08-26 Basf Se Boron containing perylene monoimides, a process for their production, their use as building blocks for the production of perylene monoimide derivatives, monoimide derivatives and their use in dye-sensitized solar cells
ES2952387T3 (es) 2013-02-08 2023-10-31 Us Health Atenuación del virus respiratorio sincitial humano mediante la desoptimización de pares de codones a escala genómica
WO2014160463A1 (en) 2013-03-13 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Prefusion rsv f proteins and their use
US9738689B2 (en) * 2013-03-13 2017-08-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Prefusion RSV F proteins and their use

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001089562A1 (en) * 2000-05-25 2001-11-29 Medimmune, Inc. F-protein epitope-based vaccine for respiratory syncytial virus infection
CN103842374A (zh) * 2011-05-13 2014-06-04 诺华股份有限公司 融合前的rsv f抗原
CA2905571A1 (en) * 2013-03-14 2014-09-18 Mucosis B.V. Heat-stable respiratory syncytial virus prefusion f protein oligomers and their use in immunological compositions
WO2014152534A1 (en) * 2013-03-14 2014-09-25 Emory University Recombinant rsv with silent mutations, vaccines, and methods related thereto

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ANNE L HOTARD ET AL: "Identification of Residues in the Human Respiratory Syncytial Virus Fusion Protein That Modulate Fusion Activity and Pathogenesis", 《J VIROL》 *

Also Published As

Publication number Publication date
US12257296B2 (en) 2025-03-25
JP2019500320A (ja) 2019-01-10
JP7311872B2 (ja) 2023-07-20
SG11201803581VA (en) 2018-05-30
EP3368547A1 (en) 2018-09-05
JP2023100654A (ja) 2023-07-19
MX2018005462A (es) 2018-08-01
WO2017075125A1 (en) 2017-05-04
CA3003726A1 (en) 2017-05-04
BR112018008708A2 (en) 2018-11-06
KR20180085730A (ko) 2018-07-27
US20230293660A1 (en) 2023-09-21
US20180333477A1 (en) 2018-11-22
US11235050B2 (en) 2022-02-01
EP3368547A4 (en) 2019-06-05

Similar Documents

Publication Publication Date Title
US12257296B2 (en) Chimeric RSV, immunogenic compositions, and methods of use
US12186386B2 (en) Recombinant RSV with silent mutations, vaccines, and methods related thereto
US20220125909A1 (en) Chimeric rsv and hmpv f proteins, immunogenic compositions, and methods of use
US20240082385A1 (en) Rsv vaccines and methods of administering same
CA2906606C (en) Recombinant rsv with silent mutations, vaccines, and methods related thereto

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination